Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Prostatic Neoplasms 30Lung Neoplasms 30Carcinoma, Non-Small-Cell Lung 26Leukemia, Myeloid, Acute 25Multiple Myeloma 22Breast Neoplasms 20Lymphoma 18Carcinoma, Renal Cell 17Urinary Bladder Neoplasms 15Leukemia, Lymphocytic, Chronic, B-Cell 15Myelodysplastic Syndromes 14Lymphoma, Large B-Cell, Diffuse 14Colorectal Neoplasms 14Pancreatic Neoplasms 11Neoplasm Metastasis 11Ovarian Neoplasms 10Myeloproliferative Disorders 10Mouth Neoplasms 10Glioma 10Glioblastoma 10Burkitt Lymphoma 10Squamous Cell Carcinoma of Head and Neck 9Triple Negative Breast Neoplasms 8Sarcoma 8Rectal Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Melanoma 8Lymphoma, Non-Hodgkin 8Laryngeal Neoplasms 8Carcinoma 8

Interventions

Specimen Handling 2Magnetic Resonance Spectroscopy 2olaparib 1exemestane 1abemaciclib 1X-Rays 1Tamoxifen 1Letrozole 1Gonadotropin-Releasing Hormone 1Fulvestrant 1Fluorodeoxyglucose F18 1Estradiol 1Biopsy 1Anastrozole 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Anatomic Stage III Breast Cancer AJCC v8 × Specimen Handling × Clear all
NCT06179303 2026-04-16

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

University of Washington

Phase 2 Recruiting
60 enrolled
Breast

Anatomic Stage III Breast Cancer AJCC v8

NCT05967286 2024-03-20

Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial

National Cancer Institute (NCI)

Phase 2 Withdrawn
Breast

Anatomic Stage III Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡